Pavmed Inc. current report, 23 February 2021

Business Context and Reporting Period

Pavmed Inc. (PAVM), an emerging growth company, filed this Form 8-K on February 23, 2021, to report the entry into a material definitive agreement. The filing details an underwritten public offering of common stock executed with Cantor Fitzgerald & Co.

Key Financial Metrics and Transaction Details

  • Offering Structure: The underwriter committed to purchase 9,782,609 shares of common stock (Firm Shares), with a 30-day option to purchase up to 1,467,391 additional shares (Option Shares).
  • Net Proceeds: The Company expects to receive approximately $41.2 million from the sale of Firm Shares, after deducting underwriter discounts, commissions, and approximately $0.4 million in estimated offering expenses.
  • Stock Price: The last reported sale price on the Nasdaq Capital Market was $5.55 per share on February 22, 2021.
  • Debt and Liquidity: The filing does not provide specific current debt balances or liquidity ratios. However, the Company intends to use net proceeds to repay all outstanding debt, including convertible notes, subject to agreement on repayment terms.

Material Changes and Use of Proceeds

The primary material change is the execution of the Underwriting Agreement to raise capital. The Company explicitly stated its intention to use the net proceeds to:

  1. Repay all outstanding debt, including convertible notes.
  2. Allocate the remaining balance to working capital and general corporate purposes.

Outlook, Risks, and Unusual Items

Closing Timeline: The Offering is expected to close on or about February 25, 2021, subject to customary closing conditions. (Note: The source text contains a typographical error stating "February 25, 2018," which is contextually inconsistent with the 2021 filing date and is interpreted as 2021).

Risks and Contingencies: The repayment of outstanding debt is contingent upon the Company agreeing with debt holders on the terms of repayment. The Underwriting Agreement includes customary representations, warranties, and indemnification obligations.

Investor Verification Checklist

  • Verify the final closing date of the offering and whether the option shares were exercised.
  • Confirm the specific terms agreed upon with holders of convertible notes regarding debt repayment.
  • Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
  • Check subsequent filings for the actual net proceeds received versus the estimated $41.2 million.